Duke University School of Medicine

XyloCor Therapeutics Reports Sustained Results in 12-Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Retrieved on: 
Martedì, Luglio 18, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Exercise, Heart, Duke University School of Medicine, Angina, Cardiovascular disease, Chest pain, Blood, Nitroglycerin, Patient, Joe Byrd (Cherokee Nation Principal Chief), Therapy, Safety, TED, Pharmaceutical industry

Earlier this year, XyloCor reported positive results from the primary study period for the Phase 2 portion EXACT trial at six months.

Key Points: 
  • Earlier this year, XyloCor reported positive results from the primary study period for the Phase 2 portion EXACT trial at six months.
  • “These 12-month data build upon the positive results achieved at the 3- and 6-month marks of the trial.
  • The six-month primary study period in the Phase 2 portion of the EXACT trial was followed by a month 12 follow up period.
  • "These results further enhance our confidence that we are on the right path for transforming outcomes in cardiovascular disease.”

THE HOWARD AND GEORGEANNA JONES FOUNDATION FOR REPRODUCTIVE MEDICINE ANNOUNCES NEW BOARD MEMBERS

Retrieved on: 
Giovedì, Luglio 13, 2023
Bioethics, Reproductive medicine, Obstetrics, Education, Genetics, W. Alton Jones Foundation, Hughes, DRS, Infertility, Physician, Gynaecology, Duke University School of Medicine, Human Molecular Genetics, Management, Nursing

VIRGINIA BEACH, Va., July 13, 2023 /PRNewswire/ -- The Jones Foundation announced today that three physicians have joined the organization's Board of Directors:

Key Points: 
  • Nonprofit research organization dedicated to advancing scientific and medical research in the field of reproductive medicine announces new Board members.
  • The Jones Foundation is a non-profit organization dedicated to advancing scientific and medical research in the field of reproductive medicine.
  • The Foundation seeks to find solutions to infertility and improve reproductive health by funding vital research and advancing public and professional discourse to shape the bioethics of reproductive medicine.
  • Howard and Georgeanna Jones," commented Mr. Jones.

New Study Shows a Coordinated Care Approach Significantly Improves Quality of Care for Patients with Type 2 Diabetes and Heart Disease

Retrieved on: 
Lunedì, Giugno 26, 2023
Myocardial infarction, Enzyme inhibitor, Diabetes, Education, Hospital, Feedback, Importance, Stroke, Duke University School of Medicine, Type 2 diabetes, Prescription, Woman, Cardiology, SGLT2, Associate, Patient, American Diabetes Association, ACE inhibitor, ASCVD, Moyamoya disease, Health, MPH, ADA, T2D, Asterixis, Pharmaceutical industry, Nursing, MD, Medicine

SAN DIEGO, June 26, 2023  /PRNewswire/ -- Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), commonly known as heart disease. The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego, CA.

Key Points: 
  • The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego, CA.
  • In the United States alone, up to two-thirds of patients with T2D develop ASCVD in their lifetime.
  • While ASCVD is associated with worse health outcomes in patients with diabetes compared to the general population, evidence-based therapies to reduce heart disease risk in adults with T2D are underused in clinical practice.
  • Findings show that coordinated care intervention can significantly improve the quality of care that high risk patients receive.

Duke University Selects Canvas LMS, Additional Instructure Learning Platform Solutions to Enable Accessible, High-Quality Learning

Retrieved on: 
Giovedì, Giugno 1, 2023
Learning, Duke University, Partnership, University, Duke University School of Medicine, Business, Teaching, Duke and Sons, Fuqua School of Business, SALT, Institute of Learning Innovation, School, Student, Map, Faculty, Medicine, Management, Tutoring, Impact, Canvas, Instructure

SALT LAKE CITY, June 1, 2023 /PRNewswire/ -- Instructure, the maker of Canvas, announces that Duke University selected Canvas LMS to power innovative instruction and learning experiences across its learning institution. The decision represents a significant investment in the entire Instructure Learning Platform, with implementations of Canvas LMS, Impact, Canvas Studio and Canvas Credentials to transform teaching and learning at the university. With this deeper partnership with Duke, all of the top ten universities in the United States now use Canvas LMS.

Key Points: 
  • SALT LAKE CITY, June 1, 2023 /PRNewswire/ -- Instructure , the maker of Canvas, announces that Duke University selected Canvas LMS to power innovative instruction and learning experiences across its learning institution.
  • The decision represents a significant investment in the entire Instructure Learning Platform, with implementations of Canvas LMS, Impact, Canvas Studio and Canvas Credentials to transform teaching and learning at the university.
  • Adding the Instructure Learning Platform is a turning point for Duke's Office of Learning Innovation, as they develop effective, scalable, forward-thinking programs that support learning.
  • By adopting additional Instructure products, they will explore new possibilities, including adding alumni learning opportunities and non-credit learning for continuing studies.

CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held

Retrieved on: 
Lunedì, Maggio 29, 2023
Laughter, European Medicines Agency, Tisagenlecleucel, First Affiliated Hospital of Xinjiang Medical University, Soochow University, Patient, Shanghai University, Cell, Medicines and Healthcare products Regulatory Agency, BLA, BioValley, DLBCL, Duke University School of Medicine, EMA, CELL, Anniversary Celebration, FDA, IND, Multimedia, China Institute for Innovation and Development Strategy, Therapy, MD Anderson Cancer Center, RMB, MHRA, Speech, CMC, Medication, Bristol Myers Squibb, Implementation, CDMO, Clinical trial, Novartis, IBLA International Competition, DoubleTree, Bengbu Medical College, Pharmaceutical industry, Medical device, EU, Medicine

SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou.

Key Points: 
  • SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou.
  • "This is the 1st summit of CELL WORLD, and Hillgene Biopharma will host this summit in the long term.
  • I hope this 1st CELL WORLD Global Cell Therapy Summit will further promote the development and innovation of cell therapy industry globally and provide more thoughts and practical examples."
  • The "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration" came to a perfect end amid the laughter and joy of the banquet.

The Inner Circle Acknowledges, Vincent E. Voci, MD as a Most Trusted Plastic Surgeon 2023 for his contributions to the field of Plastic Surgery

Retrieved on: 
Martedì, Maggio 23, 2023
Plastic surgery, Music, Food, University, Face, Skin care, Replantation, American Board of Plastic Surgery, Duke University School of Medicine, ABPS, Breast, American Society of Plastic Surgeons, Private practice, Multimedia, Virginia Mason Medical Center, Continental, University of Louisville School of Medicine, American Board of Commissioners for Foreign Missions, American Society for Aesthetic Plastic Surgery, MD, Patient, Cooking, University of Washington School of Medicine, Auckland District Health Board, Henry Maier Festival Park, Plastic, General surgery, Morris Communications, American College, Society, Novant Health, Skin, Cleft lip and cleft palate, Dentistry, Nursing

CHARLOTTE, N.C., May 23, 2023 /PRNewswire/ -- Vincent E. Voci, MD, is being recognized by Continental Who's Who as a Most Trusted Plastic Surgeon 2023 for his contributions to the field of Plastic Surgery.

Key Points: 
  • CHARLOTTE, N.C., May 23, 2023 /PRNewswire/ -- Vincent E. Voci, MD, is being recognized by Continental Who's Who as a Most Trusted Plastic Surgeon 2023 for his contributions to the field of Plastic Surgery.
  • He them completed his internship and residency in general surgery at the University of Washington School of Medicine in Seattle.
  • Board-certified in plastic surgery by the American Board of Plastic Surgery (ABPS), Dr. Voci specializes in all types of cosmetic surgery and surgical procedures related to aesthetics.
  • In private practice, the doctor has 37 years of experience working at Voci Plastic Surgery in Charlotte, NC.

Study to Measure Accuracy of Unique Index for Early, Noninvasive Prediction of Worsening Heart Failure

Retrieved on: 
Giovedì, Maggio 18, 2023
Heart failure, Hospital, Hypervolemia, HF, Duke University School of Medicine, Medicine, Biomarker, HFI, Weight gain, MHS, MD, Patient, SAN, Circulation (journal), Disease, Mortality, Trial of the century, FDA, Health, Medical device, Medical imaging

SAN FRANCISCO, May 18, 2023 /PRNewswire/ -- Bodyport Inc. today introduced SCALE-HF, a multi-phase study to develop and validate a composite index to predict heart failure events using multiple noninvasive hemodynamic biomarkers gathered when a patient stands on the Bodyport Cardiac Scale. An article published in the May 2023 issue of the journal Circulation: Heart Failure describes the design of the prospective, multicenter study, which will assess the accuracy of the Heart Function Index (HFI), a novel algorithm created to help care teams remotely monitor, predict, and prevent worsening heart failure events.

Key Points: 
  • An article published in the May 2023 issue of the journal Circulation: Heart Failure describes the design of the prospective, multicenter study, which will assess the accuracy of the Heart Function Index (HFI), a novel algorithm created to help care teams remotely monitor, predict, and prevent worsening heart failure events.
  • "There are more than 6 million Americans living with heart failure, and the current standard of care for monitoring the majority is having them weigh themselves daily to identify fluid buildup, a key indicator of worsening heart failure.
  • That's what we're assessing in this study of the Heart Function Index."
  • With weight included among the scale's biomarkers, the noninvasive biosensors built into the Cardiac Scale's platform measure several FDA-cleared biomarkers of heart function and fluid status that accurately reflect worsening heart failure.

Winners of the American Liver Foundation 2023 Liver Health Poster Competition Announced

Retrieved on: 
Mercoledì, Maggio 10, 2023
Linda, Volunteering, Duke University, Fatty liver disease, ALF, Liver disease, People's Choice Awards, American Liver Foundation, Saint Louis University, Liver transplantation, Liver cancer, Patient, Mount Sinai Kravis Children's Hospital, Duke University School of Medicine, Diagnosis, Poster, Hospital, Empathy, Indonesian Choice Awards, Caregiver, Loyola University Medical Center, Dietary supplement, Medical device, Dentistry, Nursing, Food delivery, Houston Methodist Hospital, Pediatrics, MD

FAIRFIELD, N.J., May 10, 2023 /PRNewswire/ -- Winners from the American Liver Foundation's 2023 Liver Health Poster Competition were announced today. This competition showcases posters and a brief video created by early career healthcare professionals from across the country on six areas of liver educational focus: disparities in liver disease, fatty liver disease, liver cancer, liver transplantation, pediatric liver disease, and rare liver disease. Competitors are tasked with translating complicated medical information into a poster and video which can be easily understood by patients or the public.

Key Points: 
  • FAIRFIELD, N.J., May 10, 2023 /PRNewswire/ -- Winners from the American Liver Foundation 's 2023 Liver Health Poster Competition were announced today.
  • This competition showcases posters and a brief video created by early career healthcare professionals from across the country on six areas of liver educational focus: disparities in liver disease , fatty liver disease , liver cancer , liver transplantation , pediatric liver disease , and rare liver disease .
  • The 2023 Liver Health Poster Competition category winners are:
    Tanisha Ronnie, MD, Loyola University Medical Center for her presentation on liver disparities .
  • To learn more about the 2023 Liver Health Poster Competition or view all the submissions, visit: alfevents.org/poster-competition .

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 4, 2023
CIS, Doctor of Philosophy, Associate, Icahn School of Medicine at Mount Sinai, X4, MD, WHIM syndrome, Patient, Translational research, Cell, Research and development, R, University, University of Massachusetts, Therapy, WHIM, Host, Wart, Immunology, Hospital, Rare, Pediatric Blood & Cancer, Safety, Abstract, Conference call, Rheumatology, Mount Sinai, ID, Immune system, Duke University School of Medicine, Federation of Clinical Immunology Societies, Annual Review of Cancer Biology, Restricted, ANC, SG, Clinical trial, Harvard Medical School, State Administrative Expenses, Annual general meeting, Upcoming, Pharmaceutical industry, Medical imaging, Dentistry, Management, Myelokathexis, Pediatrics, Conference, Hypogammaglobulinemia, Infection, Medicine

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023 and highlighted key upcoming expected milestones.

Key Points: 
  • “This is an exciting time at X4 as we look forward to delivering on several expected major milestones throughout the rest of 2023,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $94.4 million in cash, cash equivalents, and restricted cash as of March 31, 2023.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

Research Study on Comfort of the New FLUME Catheter to Begin Recruitment

Retrieved on: 
Venerdì, Aprile 28, 2023
Health, Medical Devices, Other Health, General Health, Clinical Trials, Research, Science, Partnership, Drainage, TFCC, Duke University School of Medicine, Quality of life, Penn State Health Children's Hospital, Multimedia, Catheter, Cardiac catheterization, Patient, Division, Medical Center, Penn State University College of Medicine, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Surgery, Food, Pennsylvania State University, Medical device, Medicine, Urology

The Flume Catheter Company Ltd. (TFCC), a medical device company dedicated to developing an improved alternative to the Foley indwelling urinary catheter, announced the launch of a study to gather real-world data on patient experiences with the new FLUME catheter.

Key Points: 
  • The Flume Catheter Company Ltd. (TFCC), a medical device company dedicated to developing an improved alternative to the Foley indwelling urinary catheter, announced the launch of a study to gather real-world data on patient experiences with the new FLUME catheter.
  • The FLUME catheter is distinguished by an alternative balloon configuration, designed to envelop the tip of the catheter upon inflation and, thereby, allow the emptying bladder to come into contact with the compliant balloon rather than a rigid catheter tip.
  • , FLUME Catheter Comfort Study Principal Investigator, and associate professor of Surgery in the Division of Urology at Duke University School of Medicine .
  • This could be game-changer for these patients.”
    The new study will help researchers learn more about whether the FLUME catheter may improve patients’ perceptions around comfort and quality of life.